肿瘤免疫治疗中的人源化小鼠模型开发及应用研讨会
肿瘤的免疫治疗日益受到社会关注与重视，随着新型免疫治疗，特别是针对免疫检查点靶向药物的蓬勃发展，已成为当下肿瘤治疗领域最具前景的发展方向之一。转化医学作为肿瘤基础研究和临床免疫治疗之间的桥梁，通过对特异性生物标志物的发掘，来优化临床研究设计，并探索最佳的药物联合治疗模式。其中，动物实验往往是转化医学研究的第一步。
本次研讨会是由和铂医药主办，并邀请Jackson laboratory和上海南方模式生物专家针对肿瘤免疫治疗中的人源化小鼠模型开发及应用进行交流。
时间：2019年10月31日13:00-15:00
地点：上海实验动物中心一号楼一号报告厅
演讲嘉宾
James Keck
Senior Director, In Vivo Pharmacology & Clinical Lab Services, Jackson Laboratory
In Jackson Laboratory, Dr.Keck has overall responsibility for the innovativearray of new scientific tools and services based on proprietary capabilities inhumanized mice and genomics to facilitate discovery and development of new waysto treat human disease. The preclinical efficacy studies using PDX and other models hu- NSGTM miceis under his direction. In addition, Dr.Keck was also responsible for the initiation of business development activities with corporations for the purpose of developing cutting edge platform based programs.
Topic：Theuse of humanized mice for immuno-oncology research and drug development.
Ruilin Sun
Vice president, Shanghai Model Organisms Center, Inc
Topic: The use of genetically modified mice for immuno-oncology research and durg development.
你也可能感兴趣
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
